Lead Product(s) : Pregabalin,Nortriptyline
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Launch of AFD-NP Product for Neuropathic Pain Management
Details : AFD-NP is a combination of Nortriptyline and Pregabalin which has approved for the treatment of moderate to severe neuropathic pain.
Product Name : AFD-NP
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2023
Lead Product(s) : Pregabalin,Nortriptyline
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nortriptyline
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Cadila Gets USFDA Nod for Antidepressant Drug
Details : Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Nortriptyline Hydrochloride capsules USP, in strengths of 10 mg, 25 mg, 50 mg and 75 mg, Cadila Healthcare said in a regulatory filing.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 25, 2021
Lead Product(s) : Nortriptyline
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
